Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL5238463

CC(C)O.CCCCCC.CCNCC.O=C(O)C(F)(F)F

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CCKAR

The experimentally established mechanism targets of Trifluoroacetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
FAAH O00519 8/20 0.44
EPHX1 P07099 1/20 0.43
CES1 P23141 5/20 0.42
CES2 O00748 4/20 0.42
MEN1 O00255 1/20 0.42
CYP1A2 P05177 1/20 0.42
KMT2A Q03164 1/20 0.42
HSD17B10 Q99714 1/20 0.42
S1PR1 P21453 5/20 0.40
S1PR3 Q99500 5/20 0.40
S1PR2 O95136 4/20 0.40
S1PR5 Q9H228 3/20 0.40
GPR84 Q9NQS5 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL28562828 0.98 FAAH (0.42) FAAHEPHX1CES1CES2MEN1
Trifluoroacetic Acid SCHEMBL28392985 0.96 FAAH (0.41) FAAHEPHX1CES1CES2MEN1
Trifluoroacetic Acid SCHEMBL28395953 0.92 FAAH (0.50) FAAHEPHX1CES1CES2MEN1
Trifluoroacetic Acid SCHEMBL3673750 0.90 FAAH (0.52) FAAHEPHX1CES1CES2MEN1
Trifluoroacetic Acid SCHEMBL28925949 0.88 FUCA1 (0.33) S1PR1S1PR3S1PR2S1PR5
Trifluoroacetic Acid SCHEMBL5494836 0.88 FAAH (0.47) FAAHEPHX1CES1CES2MEN1
Trifluoroacetic Acid SCHEMBL28128351 0.88 FAAH (0.50) FAAHEPHX1CES1CES2MEN1
Decane SCHEMBL6353937 0.88 FAAH (0.54) FAAHEPHX1CES1CES2MEN1
Heptane SCHEMBL3918420 0.88 FAAH (0.54) FAAHEPHX1CES1CES2MEN1
Trifluoroacetic Acid SCHEMBL28015086 0.86 FAAH (0.48) FAAHEPHX1CES1CES2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115963217-B Detection method of imidapril intermediate and impurity 北京阳光诺和药物研究股份有限公司 2023-09-22 CN disclosed
CN-115963217-A Method for detecting imidapril intermediate and impurities 北京阳光诺和药物研究股份有限公司 2023-04-14 CN disclosed
CN-111175387-B Method for detecting milnacipran isomer 成都康弘药业集团股份有限公司 2022-06-07 CN disclosed
CN-111175387-A Method for detecting milnacipran isomer 成都康弘药业集团股份有限公司 2020-05-19 CN disclosed
CN-108226319-A A kind of method for detecting optical isomer in Rivastigmine patch 亚宝药业集团股份有限公司 2018-06-29 CN disclosed
CN-104792913-B A kind of Apremilast and the method for separating and detecting of enantiomer thereof 苏州亚宝药物研发有限公司 2016-08-24 CN disclosed
CN-104330501-B A kind of high performance liquid chromatography detects the method for rivastigmine-hydrogentartrate optical isomer JIANGSU ZHENGDA FENGHAI PHARMACEUTICAL CO., LTD. (CN) 2016-01-20 CN disclosed
CN-104792913-A Separation detection method of apremilast and apremilast enantiomer SUZHOU YABAO PHARMACEUTICAL RES AND DEV CO LTD 2015-07-22 CN disclosed
CN-104330501-A Method for detecting rivastigmine tartrate optical isomer by high performance liquid chromatography JIANGSU CHIA TAI FENGHAI PHARMACEUTICAL CO LTD 2015-02-04 CN disclosed
EP-1819690-A2 CHROMAN COMPOUNDS Pfizer Limited (GB) 2007-08-22 EP disclosed
WO-2006056850-A2 CHROMAN COMPOUNDS PFIZER LIMITED (GB) 2006-06-01 WO disclosed
US-6251904-B1 Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction PFIZER INC. 2001-06-26 US disclosed